Clinical Trials Browser

Phase 2 × Neuroblastoma × AZD 6244 × Clear all

NCT03213691 2025-02-05

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

21 enrolled 11 charts

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms